Unicycive Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
UNCY$3.66-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2025
Balance Sheets
(In thousands, except for share and per share amounts)
| As of | As of | |
|---|---|---|
| December 31, | December 31, | |
| 2024 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $26,142 | $29,198 |
| Prepaid expenses and other current assets | 4,806 | 7,692 |
| Marketable securities | - | 12,071 |
| Total current assets | 30,948 | 48,961 |
| Right of use asset, net | 645 | 108 |
| Property and equipment, net | 75 | 66 |
| Total assets | $31,668 | $49,135 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,058 | $383 |
| Accrued liabilities | 3,562 | 1,523 |
| Warrant liability | 18,936 | 16,915 |
| Operating lease liability - current | 564 | 117 |
| Total current liabilities | 24,120 | 18,938 |
| Operating lease liability – long term | 117 | - |
| Total liabilities | 24,237 | 18,938 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Series A-2 Prime preferred stock, $0.001 par value per share – 21,388.01 Series A-2 Prime shares authorized at December 31, 2024, and December 31, 2025; 6,150.21 and 2,265 Series A-2 Prime shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | - | - |
| Series B-2 preferred stock, $0.001 par value per share – 50,000 Series B-2 shares authorized at December 31, 2024, and December 31, 2025; 3,000 and zero Series B-2 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | - | - |
| Preferred stock, $0.001 par value per share— 10,000,000 shares authorized at December 31, 2024, and December 30, 2025; zero shares issued and outstanding at December 31, 2024, and December 31, 2025 | - | - |
| Common stock, $0.001 par value per share – 400,000,000 shares authorized at December 31, 2024, and December 31, 2025; 11,384,236 and 22,114,245 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | 11 | 22 |
| Accumulated other comprehensive loss | - | (1) |
| Additional paid-in capital | 108,690 | 158,001 |
| Accumulated deficit | (101,270) | (127,825) |
| Total stockholders’ equity | 7,431 | 30,197 |
| Total liabilities and stockholders’ equity | $31,668 | $49,135 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.